Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fornigesic is a branded generic combination analgesic marketed by Fornix Healthcare, an Indian pharmaceutical company. It is primarily formulated as a fixed-dose combination of tramadol hydrochloride (37.5 mg) and paracetamol (325 mg), although a single-ingredient tramadol injection is also available under the same brand name. Tramadol is a centrally acting synthetic opioid that provides analgesia through a dual mechanism: it acts as a weak agonist at the mu-opioid receptor and inhibits the neuronal reuptake of norepinephrine and serotonin, thereby enhancing descending inhibitory pain pathways. Paracetamol (acetaminophen) is a non-opioid analgesic and antipyretic that is thought to inhibit prostaglandin synthesis, particularly within the central nervous system. The combination of these two agents provides a synergistic effect, offering effective management for moderate to severe acute and chronic pain with a potentially improved safety profile compared to higher doses of single-agent opioids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tramadol + paracetamol.